Table 1 PHN ZQOL study patients: socio-demographic data
Characteristic | PHN patients (n = 152) |
|---|---|
Age years – mean (Range) | 71.5 (50 – 96) |
Gender n (%) | |
male | 57 (37.5%) |
female n (%) | 95 (62.5%) |
Body Mass Index (BMI) – mean (Range) | 27.4 (18 – 44) |
Ethnicity n (%) | |
White/Caucasian | 150 (98.7%) |
Afro-Caribbean | 1 (0.7%) |
Mixed race | 1 (0.7%) |
Comorbidities n (%) | |
Any comorbid disorder | 141 (92.8%) |
Cardiovascular | 98 (64.5%) |
Immune | 6 (3.9%) |
Metabolic/endocrine | 39 (25.7%) |
Neoplasms | 23 (15.1%) |
Psychological/psychiatric | 46 (30.3%) |
Respiratory | 20 (13.2%) |
Rheumatoid/neurological | 88 (57.9%) |
Highest level of education n (%) | |
Secondary school or less | 69 (45.4%) |
O level or equivalent | 21 (13.8%) |
A level or equivalent | 10 (6.6%) |
Vocational | 30 (19.7%) |
Undergraduate degree | 10 (6.6%) |
Post graduate degree | 9 (5.9%) |
Other | 3 (2.0%) |
Work status n (%) | |
Full or part time employment | 21 (13.8%) |
Retired | 120 (78.9%) |
Unable to work due to post-herpetic neuralgia | 3 (2.0%) |
Unable to work for other medical reasons | 5 (3.3%) |
Other | 3 (2.0%) |
Living situation n (%) | |
Living alone | 53 (34.9%) |
Living with partner | 90 (59.2%) |
Living with partner and children | 2 (1.3%) |
Living with children | 2 (1.3%) |
Living with friends | 1 (0.7%) |
Living in a communal residence | 0 (0%) |
Living with family | 4 (2.6%) |
Years since formal diagnosis of PHN – mean (SD) | 3.57 (5.11) |
Current prescribed treatment by type n (%) | |
Antidepressant | 90 (59%) |
WHO Level 1 analgesic | 84 (55%) |
WHO Level 2 analgesic | 76 (50%) |
Local anaesthetic/analgesic | 34 (22%) |
Topical analgesic | 26 (17%) |
WHO Level 3 analgesic | 14 (9%) |
Miscellaneous | 37 (24%) |